Ligand Pharmaceuticals Incorporated Stock Today
| LGND Stock | USD 120.00 6.07 5.33% |
PerformanceInsignificant
| Odds Of DistressVery Low
|
Ligand Pharmaceuticals is trading at 120.00 as of the 17th of February 2025, a 5.33 percent increase since the beginning of the trading day. The stock's lowest day price was 113.61. Ligand Pharmaceuticals has a very small chance of experiencing financial distress in the next few years but had a somewhat insignificant performance during the last 90 days. The performance scores are derived for the period starting the 19th of November 2024 and ending today, the 17th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 18th of November 1992 | Category Healthcare | Classification Health Care |
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company was incorporated in 1987 and is based in San Diego, California. The company has 18.9 M outstanding shares of which 951.52 K shares are now shorted by private and institutional investors with about 10.58 trading days to cover. More on Ligand Pharmaceuticals Incorporated
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Ligand Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO and Executive Director | John Higgins | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, SP Small-Cap 600, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsLigand Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Ligand Pharmaceuticals' financial leverage. It provides some insight into what part of Ligand Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ligand Pharmaceuticals Incorporated (LGND) is traded on NASDAQ Exchange in USA. It is located in 555 Heritage Drive, Jupiter, FL, United States, 33458 and employs 58 people. Ligand Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.27 B. Ligand Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 18.9 M outstanding shares of which 951.52 K shares are now shorted by private and institutional investors with about 10.58 trading days to cover.
Ligand Pharmaceuticals Incorporated currently holds about 147.94 M in cash with 49.58 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.76.
Check Ligand Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationThe majority of Ligand Pharmaceuticals outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Ligand Pharmaceuticals Incorporated to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Ligand Pharmaceuticals. Please pay attention to any change in the institutional holdings of Ligand Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.
Check Ligand Ownership Details
Ligand Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Ashford Capital Management Inc | 2024-09-30 | 310.4 K | |
| Rice Hall James & Associates, Llc | 2024-12-31 | 304.9 K | |
| Villere St Denis J & Co Llc | 2024-12-31 | 287 K | |
| Impax Asset Management Group Plc | 2024-09-30 | 280.2 K | |
| Massachusetts Financial Services Company | 2024-12-31 | 276.7 K | |
| Deutsche Bank Ag | 2024-09-30 | 273.9 K | |
| Northern Trust Corp | 2024-09-30 | 262.8 K | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 237 K | |
| Amvescap Plc. | 2024-09-30 | 188.7 K | |
| Blackrock Inc | 2024-09-30 | 3 M | |
| Vanguard Group Inc | 2024-12-31 | 2.1 M |
Ligand Pharmaceuticals Historical Income Statement
Ligand Stock Against Markets
Ligand Pharmaceuticals Corporate Management
| Vincent Antle | Senior Capitsol | Profile | |
| Paul Hadden | Senior Development | Profile | |
| Michael Jeong | Head Relations | Profile | |
| Audrey WarfieldGraham | Chief Officer | Profile | |
| Karen MD | Senior Strategy | Profile | |
| Richard Baxter | Senior Operation | Profile | |
| Todd Pettingill | Sr. Manager - Corporate Development and Investor Relations | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Ligand Pharmaceuticals Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ligand Pharmaceuticals. If investors know Ligand will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ligand Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.032 | Earnings Share 2.5 | Revenue Per Share | Quarterly Revenue Growth 0.576 | Return On Assets |
The market value of Ligand Pharmaceuticals is measured differently than its book value, which is the value of Ligand that is recorded on the company's balance sheet. Investors also form their own opinion of Ligand Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ligand Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ligand Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ligand Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ligand Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ligand Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ligand Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.